Research Analysts’ Recent Ratings Updates for MiMedx Group (MDXG)

MiMedx Group (NASDAQ: MDXG) has recently received a number of price target changes and ratings updates:

  • 12/1/2017 – MiMedx Group had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $18.00 price target on the stock.
  • 12/1/2017 – MiMedx Group had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $21.00 price target on the stock.
  • 11/24/2017 – MiMedx Group had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $18.00 price target on the stock.
  • 11/14/2017 – MiMedx Group had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $21.00 price target on the stock.
  • 10/30/2017 – MiMedx Group had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $21.00 price target on the stock.
  • 10/10/2017 – MiMedx Group was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. “

Shares of MiMedx Group, Inc (NASDAQ MDXG) opened at $11.56 on Monday. The firm has a market cap of $1,283.56, a price-to-earnings ratio of 55.05, a PEG ratio of 2.75 and a beta of 0.88. MiMedx Group, Inc has a 52 week low of $7.64 and a 52 week high of $17.47.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.08. The firm had revenue of $84.60 million for the quarter, compared to analyst estimates of $84.60 million. MiMedx Group had a net margin of 11.64% and a return on equity of 17.49%. The business’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 earnings per share. research analysts expect that MiMedx Group, Inc will post 0.24 earnings per share for the current fiscal year.

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply